120 results about "Kinin" patented technology

The invention discloses an anti-human tissue kallikrein 1 monoclonal antibody and an application thereof. The anti-human tissue kallikrein 1 monoclonal antibody comprises any one of a monoclonal antibody CELL-2, a monoclonal antibody CELL-5 or a monoclonal antibody CELL-6 or a combination of at least two of the monoclonal antibody CELL-2, the monoclonal antibody CELL-5 and the monoclonal antibody CELL-6. The anti-human tissue kallikrein 1 monoclonal antibody provided by the invention is produced by immunizing natural tissue kallikrein, and can effectively recognize tissue kallikrein in human serum / urine.

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Plasma kallikrein binding proteins and methods of using such proteins are described.

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.

To provide a plasma kallikrein inhibitor and its use.SOLUTION: The present invention provides a compound and a composition thereof, which are useful as a plasma kallikrein inhibitor and exhibit desirable properties as the inhibitor.SELECTED DRAWING: None

The present invention provides compounds and compositions thereof that are useful as inhibitors of plasma kallikrein and that exhibit desirable properties toward said plasma kallikrein.

The invention provides a KIF18 inhibitor and a synthesis method thereof, and particularly provides a compound shown as a formula (I), and the compound can regulate KIF18A protein, so that the cell cycle and the cell proliferation process are influenced to treat cancers and cancer-related diseases. Also provided are pharmaceutical compositions comprising the compounds and methods for treating conditions associated with KIF18A activity.

The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more compounds of Formula I compounds, and methods for using the compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

The invention relates to a KIF18 inhibitor with a structure as shown in a formula (I) and a synthesis method thereof, and the compound can regulate KIF18A protein so as to influence a cell cycle and a cell proliferation process to treat cancers and cancer-related diseases. And pharmaceutical compositions comprising the compounds, methods for treating conditions associated with KIF18A activity.

Methods and compositions for controlling, treating, preventing, or ameliorating arthropod infection are provided. Compositions can comprise one or more active agents of small molecules antagonists of arthropod kinin receptor. Methods of preventing disease development and infestation by arthropods are disclosed as well as methods of making, using, and producing such compositions.

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

The present invention relates to human tissue kallikrein 7 (KLK7) selective inhibitor compounds, combinations including these compounds, process to obtain the referred compounds, and methods of using the same. The present invention belongs to the field of chemistry, pharmacology and medicine.

The application belongs to the technical field of cosmetics and skin external preparation, and discloses a retinoid, a preparation method and application thereof. The compound is formed by covalently coupling a Schiff base or a kinin releasing enzyme cleavable peptide bond (L) and a free L-amino acid, a di- to hexapeptide or a C6-C22 fatty acid ester (P) of the retinol parent (R), and the structural general formula is R-L-P. The compound has a 12-week stability rate of ≥80% in a 25℃ aqueous preparation, is recognized by a keratin layer carboxylic acid esterase and a kinin releasing enzyme KLK-5 / KLK-7 after being applied to the skin, is subjected to enzymatic cutting in a skin acidic cuticle (pH 4.5-5.5) microenvironment, and releases free retinol at a fixed point. Compared with retinol palmitate, the in-situ release efficiency of the compound of the application is increased by 2.5-4.5 times, while the risk of systemic absorption is significantly reduced, and the incidence of sensitive skin irritation is ≤6.7%.

Aspects of the application provide dual inhibitor anti-KLK5 / KLK7 antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and methods of using such proteins are described.

Compositions and methods are described for the delivery of a fully human post-translationally modified therapeutic monoclonal antibody that binds to plasma kallekrein (pKal) to a human subject diagnosed with a disease or condition indicated for treatment with an anti-pKal antibody. Compositions and methods are also described with liver specific promoter combinations to enhance gene expression in liver cells. Such diseases include hereditary angioedema, as well as ocular indications, such as diabetic retinopathy and diabetic macular edema. Dosing of viral vectors encoding the anti-pKal antibody to achieve therapeutically effective serum levels is provided.

Materials, methods, and systems for enhanced protease targeting. For example, methods for the targeting of kallikrein related peptidase 2 (KLK2) are provided.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention discloses a label-free screening method and application of an FPR1 bias agonist screened by the label-free screening method to acute lung injury. According to the invention, Epic label-free screening is combined with calcium flow screening, such that a preliminarily screened FPR1 agonist is obtained; the FPR1 biased agonist is obtained through a G protein dissociation experiment and a beta-arrest collection experiment; the FRP1 antagonist is obtained through screening of a known FPR1 agonist. The FPR1 bias agonist kinetin nucleoside is obtained for the first time, and by detecting the superoxide inhibiting, cast-off cell inhibiting and MPO inhibiting functions of the bias agonist KR, it is proved that the bias agonist KR has the function of treating acute lung injury. The invention discovers that the kinetin nucleoside has the effect of treating the acute lung injury for the first time.